GE Healthcare booth is seen ahead of the 2022 China International Fair for Trade in Services (CIFTIS) at China National Convention Center on August 28, 2022 in Beijing, China.
CareIntellect for Oncology, as the tool is called, will help oncologists get up to speed on a patient’s history and disease progression by quickly showing them the data they need, the company said. GE said it wants to spare oncologists the headache of digging through records so they can focus on caring for their patients.
Health-care data is notoriously difficult to analyze, and as much as 97% of the data produced by hospitals goes unused, according to a Deloitte report. That information is stored across numerous vendors and file formats such as images, lab test results, clinical notes and device readings, which can be extremely taxing for doctors to sort through.
“It’s very time-consuming, very frustrating for these clinicians,” Dr. Taha Kass-Hout, GE HealthCare’s global chief science and technology officer, told CNBC in an interview.
CareIntellect for Oncology will be able to summarize clinical reports and identify when patients are deviating from their treatment plans, Kass-Hout said. The system can flag when a patient misses a lab test, for instance, so that their doctor can determine the best next steps.
“For cancer patients, the treatment journey can last years and involve numerous doctor visits,” he said.
GE HealthCare’s CareIntellect for Oncology
Courtesy of GE HealthCare
CareIntellect for Oncology can also help identify relevant clinical trials that patients might be eligible for, saving oncologists hours of work, said Chelsea Vane, vice president of digital products at GE HealthCare. That process has traditionally required doctors to scroll through a database of available trials, memorize inclusion and exclusion criteria and dig through patient records to determine a good fit, Vane told CNBC.
“What we’ve done is remove that,” she said.
The purpose of the new app is to save oncologists time and effort, but if doctors want to dive into more detail, CareIntellect for Oncology allows them to view the original record that’s referenced, the company said.
GE HealthCare is planning to make CareIntellect for Oncology widely available to U.S. customers in 2025, and it will initially be optimized for prostate and breast cancers. Health organizations such as Tampa General Hospital are already evaluating it, the company said. Since the tool is cloud-based, it will drive recurring revenue for GE HealthCare, Kass-Hout said.
The company is planning to introduce additional apps under the CareIntellect brand in the future, Kass-Hout said. The oncology tool is the first offering, and health-care organizations will be able to easily pick and choose the apps that they want to enable, he added.
GE HealthCare is also hoping to integrate its CareIntellect products with some of the other early stage AI initiatives it teased on Monday.
The company highlighted five new AI products that it is developing, including a collaborative team of AI agents, a tool to predict an aggressive type of breast cancer recurrence, and a tool to flag suspicious mammography scans to radiologists more quickly.
GE HealthCare decided to preview the new tools to give customers an idea of the problems it’s trying to solve, Kass-Hout said. The company will solicit feedback from health-care organizations and work with regulators as necessary, he said.
For instance, GE HealthCare is exploring how a group of AI agents can work together as a team to support doctors through its tool called Health Companion.
The agents in Health Companion will be trained as experts in specific domains, such as radiology, pathology or genomics, and offer insights based on their expertise, Kass-Hout said. The agents could identify whether a specific symptom is a side effect of treatment or a sign of disease progression, for example, and suggest next steps, he added.
Ideally, the tool will give doctors the same kind of support they’d expect from working with a multidisciplinary team, Kass-Hout said. But while consulting a panel of experts can take days or weeks, Health Companion would be available immediately.
“At the moment, it’s an early concept,” he said. “Our aim is to elevate the standard of care and get ahead of the overburden of clinicians trying to take care of their patient.”
Bluesky has surged in popularity since the presidential election earlier this month, suddenly becoming a competitor to Elon Musk’s X and Meta’s Threads. But CEO Jay Graber has some cautionary words for potential acquirers: Bluesky is “billionaire proof.”
In an interview on Thursday with CNBC’s “Money Movers,” Graber said Bluesky’s open design is intended to give users the option of leaving the service with all of their followers, which could thwart potential acquisition efforts.
“The billionaire proof is in the way everything is designed, and so if someone bought or if the Bluesky company went down, everything is open source,” Graber said. “What happened to Twitter couldn’t happen to us in the same ways, because you would always have the option to immediately move without having to start over.”
Graber was referring to the way millions of users left Twitter, now X, after Musk purchased the company in 2022. Bluesky now has over 21 million users, still dwarfed by X and Threads, which Facebook’s parent debuted in July 2023.
X and Meta didn’t immediately respond to requests for comment.
Threads has roughly 275 million monthly users, Meta CEO Mark Zuckerberg said in October. Although Musk said in May that X has 600 million monthly users, market intelligence firm Sensor Tower estimates 318 million monthly users as of October.
Bluesky was created in 2019 as an internal Twitter project during Jack Dorsey’s second stint as CEO, and became an independent public benefit corporation in 2022. In May of this year, Dorsey said he is no longer a member of Bluesky’s board.
“In 2019, Jack had a vision for something better for social media, and so that’s why he chose me to build this, and we’re really thankful for him for setting this up, and we’ve continued to carry this out,” said Graber, who previously founded Happening, a social network focused on events. “We’re building an open-source social network that anyone can take into their own hands and build on, and it’s something that is radically different from anything that’s been done in social media before. Nobody’s been this open, this transparent and put this much control in the users hands.”
Part of Bluesky’s business plan involves offering subscriptions that would let users access special features, Graber noted. She also said that Bluesky will add more services for third-party coders as part of the startup’s “developer ecosystem.”
Graber said Bluesky has ruled out the possibility of letting advertisers send algorithmically recommended ads to users.
“There’s a lot on the road map, and I’ll tell you what we’re not going to do for monetization,” Graber said. “We’re not going to build an algorithm that just shoves ads at you, locking users in. That’s not our model.”
Bluesky has previously experienced major growth spurts. In September, it added 2 million users following X’s suspension in Brazil over content moderation policy violations in the country and related legal matters.
In October, Bluesky announced that it raised $15 million in a funding round led by Blockchain Capital. The company has raised a total of $36 million, according to Pitchbook.
Alphabet shares slid 6% Thursday, following news that the Department of Justice is calling for Google to divest its Chrome browser to put an end to its search monopoly.
The proposed break-up would, according to the DOJ in its Wednesday filing, “permanently stop Google’s control of this critical search access point and allow rival search engines the ability to access the browser that for many users is a gateway to the internet.”
This development is the latest in a years-long, bipartisan antitrust case that found in an August ruling that the search giant held an illegal monopoly in both search and text advertising, violating Section 2 of the Sherman Act.
The potential break-up would include preventing Google from entering into exclusionary agreements with competitors like Apple and Samsung, part of a set of remedies that would last 10 years.
POLAND – 2024/11/13: In this photo illustration, the NVIDIA company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)
Sopa Images | Lightrocket | Getty Images
Nvidia shares dropped in U.S. premarket trading Thursday after the tech giant’s third-quarter earnings failed to impress investors.
Shares of the chipmaker slumped 3.21% at around 5:03 a.m. ET, following the Wednesday release of Nvidia’s quarterly results, which beat on both the top and bottom lines.
Revenue came in at $35.08 billion, up 94% year-on-year and exceeding the $33.16 billion forecast by LSEG analysts. Earnings per share was 81 cents adjusted, also above analyst expectations.
Other chipmakers fell on the back of the market reaction to Nvidia’s third-quarter results. Shares of Intel, Qualcomm and Micron Technology all lost 1% or more in value, while AMD declined 0.6%.
The slump in Nvidia also had a knock-on effect on European semiconductor firms. ASML, a key chip equipment supplier, dropped 0.9%, while compatriot Dutch chip firm ASMI fell 0.5%. Chipmakers BE Semiconductor, STMicroelectronics and Infineon slipped 0.8%, 0.7 and 0.6%, respectively.
Several notable chip names were also in negative territory in Asia. TSMC, which makes Nvidia’s high-performance graphics processing units, eased as much as 1.5%. Contract electronics manufacturer Foxconn dropped 1.9%.
Why are Nvidia shares falling?
Nvidia has largely cornered the market for the high-powered chips powering the world’s most advanced artificial intelligence models, such as OpenAI’s ChatGPT.
Despite nearly doubling sales year-on-year, Nvidia’s third-quarter results showed a slowdown from previous quarters. Nvidia previously reported growth of 122% in the second quarter, 262% in the first quarter, and 265% in the fourth quarter of 2023.
Derren Nathan, head of equity research at Hargreaves Lansdown, said in emailed comments Wednesday that the dip in Nvidia’s share price “suggests even outstanding isn’t enough for some investors,” adding that he expects the stock to bounce back once markets open.
“NVIDIA’s generated stellar gains for shareholders over many years now, and right now it’s pretty hard to see any major holes in the investment case,” Nathan added.
Analysts are looking ahead to the much-anticipated launch of Nvidia’s next-generation chip called Blackwell. On the firm’s earnings call, CEO Jensen Huang said that demand for the chip is exceeding supply.